Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Several possible studies

Story checked

GLP-1 Benefits Beyond Weight Loss: Heart Health, Lower Cancer Risk And More (opens in a new tab)

today.com · 2026-09-08

Short answerEvidenceSource

Short answer

Several possible studies

No confirmed study match.

Several papers could fit this story, but none could be confirmed as its source. The claims remain unverified.

16 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Several studies could be the source of this story.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Open claim evidence
3

Search result

Several studies could fit.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Source paper

Source layer

The paper behind the story

The source record for this check.

The research anchor for the report.

The literature search

16 candidate papers

Papers surfaced in our search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 12 more search results
Then inspect each claim

Evidence layer

Claim by claim

What the story asserts. With no source study, there is nothing to check these against.

Claim 1 of 10Not checkedGLP-1 medications may have much more to offer than diabetes and obesity treatment, with research suggesting benefits ranging from heart health and cancer protection to fewer asthma attacks.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 2 of 10Not checkedKrumholz says GLP-1 drugs are a "heart drug," and the article says a paper found tirzepatide lowered systolic blood pressure by almost seven points versus placebo in people with obesity or overweight.View evidenceHide evidence

As statedalmost seven points

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 3 of 10Not checkedThe article says semaglutide reduced high-sensitivity C-reactive protein, a marker of cardiovascular inflammation, even in people who did not lose weight.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 4 of 10Not checkedThe article says GLP-1s significantly reduce obstructive sleep apnea severity, and Zepbound is described as the first FDA-approved medication for obstructive sleep apnea.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 5 of 10Not checkedThe article says Ozempic is FDA-approved to reduce the risk of worsening kidney disease, kidney failure and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 6 of 10Not checkedThe article says Wegovy is FDA-approved to treat MASH in adults with moderate-to-advanced fibrosis, and that improvement with GLP-1 drugs is "very exciting."View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 7 of 10Not checkedThe article reports that GLP-1 use was associated with a 41% lower risk of obesity-related cancers in non-diabetic obese patients, and that women with excess weight who used GLP-1s were about 30% less likely to develop breast cancer than those who did not.View evidenceHide evidence

As stated41% lower risk; about 30% less likely

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 8 of 10Not checkedThe article says people with airways diseases who took GLP-1s appeared to have fewer asthma attacks and fewer COPD flare-ups than patients given other diabetes medicines, with semaglutide associated with nearly a 40% reduction in asthma attacks and a 20% reduction in COPD flare-ups.View evidenceHide evidence

As statednearly 40% reduction; 20% reduction

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 9 of 10Not checkedThe article says semaglutide may help curb alcohol addiction, and GLP-1 use was also associated with reduced risks of substance use disorders involving opioids, stimulants and other substances in U.S. veterans with type 2 diabetes.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 10 of 10Not checkedThe article says GLP-1s do not yet have real evidence for extending longevity in healthy people without underlying health problems, and experts call that idea premature.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Finally, the search trail

Method layer

No single source study was found.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

Crossref, PubMed, Europe PMC · 16 candidate papers

Candidate

Fig. 1. Flowchart of study sample formation. CRP, C-reactive protein; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides.

Crossref

Source (opens in a new tab)

Explore all search results